• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肌醇对多囊卵巢综合征女性辅助生殖技术结局的影响：一项随机临床试验研究的系统评价和荟萃分析

The effect of myo-inositol on assisted reproductive technology outcomes in women with polycystic ovarian syndrome: A systematic review and meta-analysis of randomized clinical trial studies.

作者信息

Sene Azadeh Akbari, Saeedzarandi Maryam, Yazdizadeh Maryam, Ghaffari Seyede Razieh, Amjadi Fatemehsadat, Zandieh Zahra, Moradi Yousef

机构信息

Shahid Akbar Abadi Clinical Research Development Unit (ShACRDU), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.

Reproductive Sciences and Technology Research Center, Department of Anatomy, Iran University of Medical Sciences, Tehran, Iran.

出版信息

Int J Reprod Biomed. 2025 Jul 29;23(5):353-376. doi: 10.18502/ijrm.v23i5.19260. eCollection 2025 May.

DOI:10.18502/ijrm.v23i5.19260
PMID:40989082
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12413536/
Abstract

BACKGROUND

Conflicting evidence from clinical trials on the effects of myo-inositol and D-chiro-inositol on assisted reproductive technology (ART) outcomes in women with polycystic ovarian syndrome (PCOS) necessitates a systematic review and meta-analysis.

OBJECTIVE

To evaluate the effect of myo-inositol and D-chiro-inositol on ART outcomes in women with PCOS.

MATERIALS AND METHODS

A comprehensive search was conducted in PubMed, Scopus, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Library for studies published from January 2000-2023. Statistical analyses were performed using STATA version 17.

RESULTS

17 intervention studies were included. myo-inositol/D-chiro-inositol supplementation significantly increased the clinical pregnancy rate (RR: 1.64, 95% CI: 1.25-2.15; I = 13.5%; p = 0.32) and top-grade embryos (RR: 1.12, 95% CI: 1.02-1.23; I = 85.43%; p = 0.0001). However, it was associated with reductions in antral follicle count (WMD: -0.78, 95% CI: -1.07 to -0.49; I = 97.37%; p = 0.001) and anti-Mullerian hormone levels (WMD: -0.46, 95% CI: -0.67 to -0.25; I = 91.95%; p = 0.001).

CONCLUSION

This meta-analysis provides reliable evidence on the effects of myo-inositol/D-chiro-inositol on fertility and ovarian function in women with PCOS undergoing ART.

摘要

背景

关于肌醇和D-手性肌醇对多囊卵巢综合征（PCOS）女性辅助生殖技术（ART）结局影响的临床试验证据相互矛盾，因此有必要进行系统评价和荟萃分析。

目的

评估肌醇和D-手性肌醇对PCOS女性ART结局的影响。

材料与方法

在PubMed、Scopus、科学网、EMBASE、ClinicalTrials.gov和Cochrane图书馆中全面检索2000年1月至2023年发表的研究。使用STATA 17版进行统计分析。

结果

纳入17项干预研究。补充肌醇/D-手性肌醇显著提高了临床妊娠率（RR：1.64，95%CI：1.25 - 2.15；I² = 13.5%；p = 0.32）和优质胚胎率（RR：1.12，95%CI：1.02 - 1.23；I² = 85.43%；p = 0.0001）。然而，它与窦卵泡计数减少（WMD：-0.78，95%CI：-1.07至-0.49；I² = 97.37%；p = 0.001）和抗苗勒管激素水平降低（WMD：-0.46，95%CI：-0.67至-0.25；I² = 91.95%；p = 0.001）有关。

结论

这项荟萃分析为肌醇/D-手性肌醇对接受ART的PCOS女性生育能力和卵巢功能的影响提供了可靠证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/76388b87104c/ijrb-23-353-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/03822313e290/ijrb-23-353-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/3a33476a7f68/ijrb-23-353-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/c7a4e5bbb365/ijrb-23-353-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/ad7dd68e873e/ijrb-23-353-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/6a39004a82cf/ijrb-23-353-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/2266e0132f8c/ijrb-23-353-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/775dd7e93dbc/ijrb-23-353-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/f8900c133ede/ijrb-23-353-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/61bca48d02c9/ijrb-23-353-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/76388b87104c/ijrb-23-353-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/03822313e290/ijrb-23-353-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/3a33476a7f68/ijrb-23-353-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/c7a4e5bbb365/ijrb-23-353-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/ad7dd68e873e/ijrb-23-353-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/6a39004a82cf/ijrb-23-353-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/2266e0132f8c/ijrb-23-353-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/775dd7e93dbc/ijrb-23-353-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/f8900c133ede/ijrb-23-353-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/61bca48d02c9/ijrb-23-353-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b4b/12413536/76388b87104c/ijrb-23-353-g0010.jpg

相似文献

1
The effect of myo-inositol on assisted reproductive technology outcomes in women with polycystic ovarian syndrome: A systematic review and meta-analysis of randomized clinical trial studies.肌醇对多囊卵巢综合征女性辅助生殖技术结局的影响：一项随机临床试验研究的系统评价和荟萃分析
Int J Reprod Biomed. 2025 Jul 29;23(5):353-376. doi: 10.18502/ijrm.v23i5.19260. eCollection 2025 May.
2
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.用于患有多囊卵巢综合征、月经过少和生育力低下的女性的胰岛素增敏药物（二甲双胍、罗格列酮、吡格列酮、D-手性肌醇）。
Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. doi: 10.1002/14651858.CD003053.pub6.
3
Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes.孕期女性产前补充肌醇以预防妊娠期糖尿病。
Cochrane Database Syst Rev. 2015 Dec 17;2015(12):CD011507. doi: 10.1002/14651858.CD011507.pub2.
4
In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction.多囊卵巢综合征不孕妇女在辅助生殖过程中的体外成熟。
Cochrane Database Syst Rev. 2025 Feb 6;2(2):CD006606. doi: 10.1002/14651858.CD006606.pub5.
5
Biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART: a systematic review and meta-analysis.生物类似药与重组人促卵泡生成素α原研药用于辅助生殖技术中卵巢刺激的比较：一项系统评价和荟萃分析。
Hum Reprod. 2025 Feb 1;40(2):343-359. doi: 10.1093/humrep/deae274.
6
Volume expanders for the prevention of ovarian hyperstimulation syndrome.用于预防卵巢过度刺激综合征的扩容剂。
Cochrane Database Syst Rev. 2016 Aug 31;2016(8):CD001302. doi: 10.1002/14651858.CD001302.pub3.
7
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).针对接受体外受精加卵胞浆内单精子注射（IVF/ICSI）的女性，使用卵巢储备标志物进行个性化促性腺激素剂量选择。
Cochrane Database Syst Rev. 2018 Feb 1;2(2):CD012693. doi: 10.1002/14651858.CD012693.pub2.
8
Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials.多囊卵巢综合征患者行卵胞浆内单精子注射治疗中补充肌醇：系统评价和随机对照试验的荟萃分析。
Reprod Biomed Online. 2017 Nov;35(5):529-535. doi: 10.1016/j.rbmo.2017.07.005. Epub 2017 Jul 14.
9
Antioxidants for female subfertility.用于女性生育力低下的抗氧化剂。
Cochrane Database Syst Rev. 2017 Jul 28;7(7):CD007807. doi: 10.1002/14651858.CD007807.pub3.
10
FSH replaced by low-dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques.在辅助生殖技术中，卵泡晚期用低剂量人绒毛膜促性腺激素替代促卵泡激素与持续使用促卵泡激素的比较。
Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD010042. doi: 10.1002/14651858.CD010042.pub2.